Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pathology and immunology of lupus glomerulonephritis: can we bridge the two?

  • 124 Accesses

  • 6 Citations

Abstract

Aberrant immune responses underwrite lupus glomerulonephritis and may contribute to glomerular cell proliferation and inflammation. Recent studies provide evidence that apoptotic immune cells may initiate immune events leading to tissue damage. Nucleosomes within apoptotic particles are recognized by B cells and other antigen presenting cells and represent the most likely inciting antigen for autoantibody production. Some of these antibodies are nephritogenic depending on fine structural composition and antigen recognition in the circulation or on renal cells. Deficient complement components contribute to reduced clearance of circulating and native kidney apoptotic cells. This review summarizes current concepts in lupus immune pathogenesis and attempts to bridge immunology to pathology of lupus glomerulonephritis.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15(2):241–50

  2. 2.

    Nasr SH, Markowitz GS (2006) The ISN/RPS 2003 Revised Classification of Lupus Nephritis: What Have we learned? Adv Anat Pathol 13(3):142–3

  3. 3.

    McHugh NJ (2002) Systemic lupus erythematosus and dysregulated apoptosis – what is the evidence? Rheumatology 41:242–245

  4. 4.

    Tsokos GC, Boumpas DT (2001) Systemic Lupus Erythematosus. In: Theofilopoulos AN, Bona C (eds) Molecular Pathology of Autoimmunity. 2nd edn Gordon and Breach, Harwood Academic Publishers, 255–281

  5. 5.

    Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620–1628

  6. 6.

    Faaber P, Rijke GPM, Van de Putte, et al: (1986) Crossreactivity of human and murine anti-DNA antibodies with heparan sulfate: the major glycosaminoglycan in glomerular basement membrane. J Clin Invest 77:1824–1830

  7. 7.

    Amoura Z, Pietter JC, Bach JF, Koutouzov S (2000) The role of nucleosomes in lupus. Curr Opin Rheumatol 12:369–73

  8. 8.

    Madaio MP, Shlomchik MJ (1996) Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis: B cells have multiple roles; all autoantibodes are not equal. J Am Soc Nephrol 7:387–396

  9. 9.

    James JA, Harley JB, Scofield RH (2001) Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol (Rev) 13:370–376

  10. 10.

    Theofilopoulos AN, Kono DH (2002) A genetic analysis of lupus. Allergy 57 (Suppl 72):S67–S74

  11. 11.

    Walport MJ, Davies KA, Botto M (1998) Clq and systemic lupus erythematosus. Review. Immunobiology 199:265–285

  12. 12.

    Tsokos GC, Wong HK, Enyedy EJ et al (2000) Immune cell signaling in lupus. Curr Opin Rheumatol 12:355–363

  13. 13.

    Tsokos GC, Liossis SNC (1999) Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 20:119–24

  14. 14.

    Liossis SNC, Tsokos GC (2006). B cell abnormalities in systemic lupus Erythematosus. In:Wallace DJ, Hahn BH (eds) Dubois’ Lupus Erythematosus, 7th Edn Lippincott,Williams and Wilkins

  15. 15.

    Watanabe D, Suda T, Hashimoto H et al (1995) Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 14:12–18

  16. 16.

    Cheng J, Zhou T, Liu C et al (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 265(5154):1759–1762

  17. 17.

    Tsokos GC (2003) Overview of Cellular Immune function in Systemic Lupus Erythematosus. In: Lahita RG (ed) Systemic Lupus Erythematosus, 4th edn, Academic Press, New York

  18. 18.

    Botto M (2001) Links between complement deficiency and apoptosis. Arthritis Res 3:207–10

  19. 19.

    Botto M et al (1999) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19:56–59

  20. 20.

    Seligman VA, Suarez C, Lum R et al (2001) The Fc gamma receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 44:618–625

  21. 21.

    Madaio MP, Yanase K (1998) Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J Autoimmun 11:535–538

  22. 22.

    Vlahakos DV, Foster MH, Adams S et al (1993) Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 41:1690–1700

  23. 23.

    Singh AK, Gangemi RM (1994) The role of VL gene structural determinants in the fine specificity of anti-DNA antibodies. Autoimmunity 18:65–75

  24. 24.

    Roberts JL, Wyatt RJ, Schwartz MM, Lewis EJ (1983) Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis. Clin Immunol Immunopathol 29:223–41

  25. 25.

    Jennette JC, Iskandar SS, Dalldorf FG (1983) Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 24:377–385

  26. 26.

    Hass M (1994) IgG subclass deposits in glomeruli of lupus and non-lupus membranous nephropathies. Am J Kidney Dis 23:358–64

  27. 27.

    Ravirajan CT, Rowse L, MacGown JR, Isenberg DA (2001) An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology 40:1405–12 (Oxford)

  28. 28.

    Wener MH, Mannik M, Schwartz MM, Lewis EJ (1987) Relationship between renal pathology and the size of circulating immune complexes in patients with systemic lupus erythematosus. Medicine (Baltimore) 66:85–97

  29. 29.

    Clynes R, Dumitru C, Ravetch JV (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279(5353):1052–1054

  30. 30.

    Charney DA, Nassar G, Truong L, Nadasdy T (2000) ”Pauci-Immune” proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome. Am J Kidney Dis 35:1193–206

  31. 31.

    Mooskeker MS, Cheney RE (1995) Unconventional myosins. Annu Rev Cell Dev Biol 11:633–675

  32. 32.

    Makino H, Sugiyama H, Yamasaki Y, Maeshima Y, Wada J, Kashihara N (2003) Glomerular cell apoptosis in human lupus nephritis. Virchows Arch 443(1):67–77

  33. 33.

    Dieker JW, van der Vlag J, Berden JH (2004) Deranged removal of apoptotic cells: its role in the genesis of lupus. Nephrol Dial Transplant 19(2):282–5

  34. 34.

    Pollak Ve, Pirani Cl (1974) Pathology of the kidney in systemic lupus erythematosus: Serial renal biopsy studies and the effects of therapy on kidney lesions. In: Dubois EL (ed) Lupus Erythematosus, 2nd ed., University of Southern California Press, Los Angeles pp 72–89

  35. 35.

    Grishman E, Churg J (1979) Ultrastructre of hematoxylin bodies in systemic lupus erythematosus. Arch Pathol Lab Med 103:573–576

  36. 36.

    Ruiz-Arguelles A, Alarcon-Segovia D (2001) Novel facts about an old marker: the LE cell. Scand J Clin Lab Invest 61(Suppl 235):S31–S37

  37. 37.

    Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP (2006) Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 168(6):1779–92

  38. 38.

    Fishelson Z, Attali G, Mevorach D (2001) Complement and apoptosis. Mol Immunol 38:207–219

  39. 39.

    Makrides SC (1998) Therapeutic inhibition of the complement system:. Pharmacol Rev 50:59–87

  40. 40.

    Niculescu F, Rus H, van Biesen T, Shin ML (1997) Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J Immunol 158:4405–4412

  41. 41.

    Manzi S, Rairie JE, Carpenter AB et al. (1996) Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178–1188

  42. 42.

    Shlomchik MJ, Madaio MP, Ni D et al. (1994) The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 180:1295–1306

  43. 43.

    Kewalramani R, Singh AK (2002) Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens 11:273–7

Download references

Author information

Correspondence to Helen Liapis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Liapis, H., Tsokos, G.C. Pathology and immunology of lupus glomerulonephritis: can we bridge the two?. Int Urol Nephrol 39, 223–231 (2007). https://doi.org/10.1007/s11255-006-9170-x

Download citation

Keywords

  • Lupus nephritis
  • Pathology
  • Apoptosis
  • Hematoxylin bodies
  • Nucleosomes